First Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia
First Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia
- 88.5% reduction of Dengue Haemorrhagic Fever shown in detailed analyses of...
Protein Sciences Receives Approval from FDA for 2014/15 Formulation of Flublok® Influenza Vaccine
MERIDEN, Conn., July 8, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine,...
MabVax Therapeutics And Telik Announce Closing of Merger
SAN DIEGO, July 9, 2014 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (Nasdaq: TELK), a publicly-traded clinical stage oncology drug...
The Cancer Immunotherapy Market Will Increase to Nearly $9 Billion Across the World's Major Pharmaceutical Markets In 2022
Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group June 30, 2014 - Burlington, Mass. – Decision Resources Group...
Novartis begins shipping flu vaccines ahead of crucial season
CAMBRIDGE, Mass., July 2, 2014 /PRNewswire/ -- Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2014-2015 season. Novartis...
Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study
New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers' Market and People in the Developing World REDWOOD CITY, Calif.,...
Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis
LEXINGTON, Mass.--(BUSINESS WIRE)--July 01, 2014-- Agenus Inc. (NASDAQ: AGEN), announced final results from a single-arm, multi-institutional, open-label, Phase 2 study showing that patients with...
Sinovac Announces Favorable Reduction in Value Added Tax Rate
BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. SVA +5.25% , a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT")...
GlycoVaxyn announces the initiation of a Phase I clinical trial in collaboration with Janssen for a vaccine against Extra-intestinal pathogenic Escherichia coli causing urinary tract infection
ZURICH-SCHLIEREN, Switzerland, Jul 1, 2014 (Canada NewsWire via COMTEX) -- GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced the initiation of a Phase 1...
CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine
- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today announced the...
FARSHAD GUIRAKHOO JOINS VAXESS TECHNOLOGIES AS CHIEF TECHNOLOGY OFFICER
Former Hookipa Biotech CSO and Sanofi/Acambis veteran to lead development of silk-based vaccine stabilization technology CAMBRIDGE, Massachusetts—June 30th, 2014—Vaxess Technologies,...
Agenus Vaccine Shows Significant Reduction in Viral Burden after HerpV Generated Immune Activation
-- Phase 2 trial in patients with genital herpes shows correlation between viral load reduction and CD8 T cell activation, an important clinical surrogate -- Trial shows booster shot...
GAVI Alliance Board approves new strategic framework to reach an additional 300 million children with vaccines
Alliance to support countries to build sustainable immunisation programmes between 2016 and 2020 to help save five to six million lives Geneva, 19 June 2014 – The GAVI Alliance Board today...
Madison Vaccines Incorporated Announces Expansion of a Phase 2 Clinical Trial for MVI-816, Its Lead DNA Vaccine for Prostate Cancer
MVI-816 Intended to Delay Metastatic Disease after Primary Therapy, but Before Hormonal Therapy Trial Now Enrolling at University of Wisconsin, with Additional Centers to Follow MADISON, WI, USA I...
GSK Statement: FDA Warning Letter - Ste-Foy Manufacturing Facility
On June 12, 2014, GSK received a Warning Letter from the U.S. Food and Drug Administration (FDA) relating to an inspection the FDA carried out in early April 2014 at our influenza vaccine...
Hilleman Laboratories announces strategic collaboration with Gotovax AB to develop next generation Oral Cholera Vaccine
Aims to offer OCVs at a significantly more affordable price than the ones currently
available in the market for developing countries
First-of-its-kind partnership undertaken to address unmet...
Gardasil® Approved in Europe for the Prevention of Anal Cancer
The European Commission granted a new indication for Gardasil®, for the prevention of anal cancer and anal precancerous lesions caused by specific oncogenic HPV types in both females and males...
PsiOxus Therapeutics Initiates 'OCTAVE' Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev
OXFORD, England, Jun 17, 2014 (BUSINESS WIRE) -- PsiOxus Therapeutics Ltd. (PsiOxus), an award-winning biotechnology company developing innovative new treatments for cancer, today announced the...
AmVac Initiates Phase III Trial with its Lead Vaccine Gynevac for the Treatment of Bacterial Vaginosis
ZUG, Switzerland, June 17, 2014 /PRNewswire via COMTEX/ -- ZUG, Switzerland, June 17, 2014 /PRNewswire/ --
Swiss-based AmVac AG, a private biotech company focused on the development of...
U.S. Biomedical Advanced Research and Development Authority (BARDA) Extends Contract with Protein Sciences Corporation
MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the U.S. Department of Health and Human Services, exercised Option Period 2 of its...
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
